Pliant Therapeutics launches $250M equity offering; prelim cash $331.2M

PLIANT THERAPEUTICS, INC.

Preliminary cash, equivalents and short-term investments of $331.2M as of Dec 31, 2022 (unaudited).
Public offering of 8.33M shares at $30/share; gross proceeds ~$250M (or ~$287.5M if overallotment exercised).
Underwriters: J.P. Morgan and Piper Sandler; offering expected to close Jan 27, 2023.
Company also granted underwriters 30-day option for up to 1.25M additional shares.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported preliminary financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: preliminary results

Exact text from the filing

Our financial statements for the quarter and year ended December 31, 2022 will not be available until after this offering is completed and consequently will not be available to you prior to investing in this offering. Based upon preliminary estimates and information available to us as of the date of this prospectus supplement, we expect to report that we had approximately $331.2 million of cash, cash equivalents and short-term investments as of December 31, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-015276

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.